Celgene Phase III Revlimid Data Show Survival Advantage In Multiple Myeloma Patients
This article was originally published in The Pink Sheet Daily
Trial also showed longest median time to disease progression, 11.3 months, reported in previously treated MM patients in a Phase III study.
You may also be interested in...
Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.
Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.
Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.